Tensegrity Pharma, Inc.

Based in Tokyo, Japan, and founded in 2023 by CEO Takahito Nakahara, Ph. D. , Tensegrity Pharma, Inc operates as a provider of drug discovery services to pharmaceutical companies, focusing on eliminating bottlenecks in the development of new therapeutic drugs and advancing them to clinical validation. In November 2024, Tensegrity Pharma, Inc raised JPY 500 million in seed funding from Newton Biocapital Partners.

Tensegrity Pharma specializes in the development of advanced pharmaceutical solutions, focusing predominantly on biologics and specialty medicines. The company's core product offerings address complex medical conditions, with a focus on rare diseases and unmet medical needs. These products improve patient outcomes through targeted therapeutic mechanisms and are utilized across various clinical settings. Tensegrity Pharma targets hospitals, specialty clinics, and pharmaceutical distributors in North America and Europe.

Tensegrity Pharma generates revenue primarily through direct sales and partnerships with healthcare institutions. Transactions typically involve direct sales of flagship products to hospitals and specialty pharmacies, with pricing reflecting the complexity and development costs of their advanced therapeutic solutions. The company will utilize this funding for the development of its therapeutic drug for cachexia or wasting syndrome.